Full text in PMC for BioSystems (Select 1404798) - PMC

Select item 46294421.

Mechanisms of resistance to EGFR tyrosine kinase inhibitors

Lihua Huang, Liwu Fu

Acta Pharm Sin B. 2015 Sep; 5(5): 390–401. Published online 2015 Jul 26. doi: 10.1016/j.apsb.2015.07.001

PMCID:: PMC4629442

Select item 44511192.

Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer

Bin-Bing S. Zhou, Michael Peyton, Biao He, Changnian Liu, Luc Girard, Eian Caudler, Yvonne Lo, Frederic Baribaud, Iwao Mikami, Noemi Reguart, Gengjie Yang, Yanlong Li, Wenqing Yao, Kris Vaddi, Adi F. Gazdar, Steven M. Friedman, David M. Jablons, Robert C. Newton, Jordan S. Fridman, John D. Minna, Peggy A. Scherle

Cancer Cell. Author manuscript; available in PMC 2015 Jun 2.

Published in final edited form as: Cancer Cell. 2006 Jul; 10(1): 39–50. doi: 10.1016/j.ccr.2006.05.024

PMCID:: PMC4451119

Article PDF–2.8M

Select item 42594193.

AXL kinase as a novel target for cancer therapy

Xiaoliang Wu, Xuewen Liu, Sanjay Koul, Chang Youl Lee, Zhenfeng Zhang, Balazs Halmos

Oncotarget. 2014 Oct; 5(20): 9546–9563. Published online 2014 Oct 16. doi: 10.18632/oncotarget.2542

PMCID:: PMC4259419

Article PDF–2.2M

Select item 41636084.

EGFR-TKI resistance in NSCLC patients: mechanisms and strategies

Yuxin Lin, Xian Wang, Hongchuan Jin

Am J Cancer Res. 2014; 4(5): 411–435. Published online 2014 Sep 6.

PMCID:: PMC4163608

Article PDF–1.0M

Select item 40493365.

The quest to overcome resistance to EGFR-targeted therapies in cancer

Curtis R Chong, Pasi A Jänne

Nat Med. Author manuscript; available in PMC 2014 Jun 9.

Published in final edited form as: Nat Med. 2013 Nov; 19(11): 1389–1400. Published online 2013 Nov 7. doi: 10.1038/nm.3388

PMCID:: PMC4049336

Article PDF–900K

Select item 36678696.

Mechanisms of resistance to EGFR targeted therapies

Gorjan Hrustanovic, Bianca J. Lee, Trever G. Bivona

Cancer Biol Ther. 2013 Apr 1; 14(4): 304–314. Published online 2013 Jan 28. doi: 10.4161/cbt.23627

PMCID:: PMC3667869

Article PDF–897K

Select item 35897017.

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor–Resistant Disease

Kadoaki Ohashi, Yosef E. Maruvka, Franziska Michor, William Pao

J Clin Oncol. 2013 Mar 10; 31(8): 1070–1080. Published online 2013 Feb 11. doi: 10.1200/JCO.2012.43.3912

PMCID:: PMC3589701

Article PDF–319K

Select item 35776358.

Personalized Cancer Medicine: Molecular Diagnostics, Predictive biomarkers, and Drug Resistance

D Gonzalez de Castro, P A Clarke, B Al-Lazikani, P Workman

Clin Pharmacol Ther. 2013 Mar; 93(3): 252–259. Prepublished online 2012 Dec 7. Published online 2013 Jan 30. doi: 10.1038/clpt.2012.237

PMCID:: PMC3577635

Article PDF–813K

Select item 34756149.

Resiliency of lung cancers to EGFR inhibitor treatment unveiled offering opportunities to divide and conquer EGFR inhibitor resistance

Collin M. Blakely, Trever G. Bivona

Cancer Discov. Author manuscript; available in PMC 2013 Oct 1.

Published in final edited form as: Cancer Discov. 2012 Oct; 2(10): 872–875. doi: 10.1158/2159-8290.CD-12-0387

PMCID:: PMC3475614

Article PDF–474K

Select item 347310010.

HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR mutant lung cancers that lack the second-site EGFR T790M mutation

Ken Takezawa, Valentina Pirazzoli, Maria E. Arcila, Caroline A. Nebhan, Xiaoling Song, Elisa de Stanchina, Kadoaki Ohashi, Yelena Y. Janjigian, Paula J. Spitzler, Mary Ann Melnick, Greg J. Riely, Mark G. Kris, Vincent A. Miller, Marc Ladanyi, Katerina Politi, William Pao

Cancer Discov. Author manuscript; available in PMC 2013 Oct 1.

Published in final edited form as: Cancer Discov. 2012 Oct; 2(10): 922–933. Published online 2012 Sep 5. doi: 10.1158/2159-8290.CD-12-0108